Details of the Drug Reposition

General Information of This Drug (ID: DMTNQB0)

Drug Name
CC-486   DMTNQB0
Synonyms
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 3 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 J Clin Oncol 33, 2015 (suppl, abstr TPS7097).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)